What You’ll Learn
A quick guide to:
- Why “natural” does not mean risk-free
- Why limited human evidence itself is a safety concern
- What can go wrong with experimental peptides or incorrect dosing
- Which peptide medicines have established safety data
- Why compounded, counterfeit, and “research-grade” products are different
- How to recognize a safer route to peptide treatment
Peptides are often marketed using reassuring words: natural, bioidentical, or made from amino acids. But, a molecule does not necessarily become safe because it resembles something already found naturally in the body.
This is the third article in our peptide-focused chapter within Hype vs. Reality. Having explored what peptides are and which ones are attracting the most attention, we now turn to perhaps the most important question: what are the risks?
Our aim is not to be pessimistic about peptides, many of which hold genuine therapeutic promise, but to look carefully at what the evidence currently tells us about their benefits, uncertainties, and potential harms.
Sometimes the Biggest Risk Is What We Do Not Know
A well-studied drug can have known side effects. An experimental peptide presents an additional problem: it may have risks we have not yet identified.
Clinical trials establish appropriate doses, how a drug behaves in the body, its adverse effects, and which patients should avoid it. When those studies have not been performed, the absence of reported harm should not be confused with evidence of safety [1].
BPC-157 is a good example. Animal studies suggest interesting effects on tissue repair, but a 2026 review found that fewer than 30 people in total had been studied in published human research, across several small, uncontrolled studies. This means the available human evidence is still far too limited to draw firm conclusions about effectiveness or safety. There is no validated dosing regimen, approved pharmaceutical formulation, or completed Phase II clinical trial [2].
Similar caution applies to CJC-1295 and ipamorelin, which stimulate the growth hormone–IGF-1 pathway. Human evidence for many performance, body composition, and longevity claims remains limited [3]. These peptides can affect blood sugar and hormone levels and have been associated with fluid retention, joint or muscle symptoms, appetite changes, and injection-site reactions.
Because growth hormone and IGF-1 also promote cell growth and survival, there is a theoretical concern that chronically stimulating this pathway could encourage the growth of existing abnormal cells. However, whether long-term use of these peptides increases cancer risk in healthy people has not been established.
What Can Actually Go Wrong?
Using an unauthorized peptide, or simply using the wrong dose, can disrupt the body’s systems these compounds are designed to influence.
Incorrect concentrations may cause accidental overdosing. Manufacturing impurities can provoke unwanted immune or allergic reactions, while poor sterility creates a risk of infection [10].
Even established peptide medicines can become dangerous when dosing goes wrong. In one case series involving compounded semaglutide, two people accidentally injected ten times the intended dose, developing substantial nausea, vomiting, and abdominal pain; one required intravenous fluids [9].
Importantly, not every complexity appears immediately. Hormonal, metabolic, or immune effects may emerge only after repeated or long-term exposure, precisely where evidence for many experimental peptides is weakest.
Product Quality Is Part Of The Risk
With unauthorized peptides, there may be two simultaneous uncertainties:
What does the molecule do to people?
Are the contents of the vial actually what the label say?
Approved medicines are manufactured under controlled standards for identity, purity, dose, and sterility. Many peptides sold online for recovery, performance, or longevity are instead marketed as “research-use” products and do not pass through the same approval and quality-control systems [1].
“Research use only” is not an alternative medical approval pathway. It generally means the product has not been authorized as a medicine for human use.
Self-injection adds further risks from dosing errors, contamination, and infection, while unregulated products may not contain the concentration, or even the compound, claimed on the label.
GLP-1 Medicines Are Different But Not Risk-Free
GLP-1–based medicines sit in a very different evidence category.
Semaglutide, tirzepatide, and liraglutide (leading GLP-1–based medicines) have been evaluated in large randomized trials involving thousands of participants, and regulated formulations are authorized for diabetes, obesity, or both, depending on the drug and jurisdiction [4-6].
For weight management, examples include Wegovy (semaglutide), Saxenda (liraglutide), and tirzepatide products such as Zepbound or Mounjaro, depending on the country and indication. Ozempic also contains semaglutide but is primarily authorized for type 2 diabetes.
“Approved,” however, does not mean harmless. Common adverse effects include nausea, vomiting, diarrhea, and constipation. Gallbladder-related problems can also occur, and clinicians must consider other complications, contraindications, and interactions [4,5].
Still, when these medicines are used appropriately in people for whom they are indicated, the evidence supports a favorable benefit-risk balance [5]. The safer route is therefore an authorized product prescribed by a qualified healthcare professional and dispensed through a regulated pharmacy, with appropriate dosing and follow-up.
The Same Molecule Does Not Always Mean The Same Product
High demand for GLP-1 medicines has also created a market for compounded and unauthorized versions.
Compounding is not automatically the same as counterfeiting and can serve legitimate medical needs. However, a compounded formulation should not always be assumed to have the same evidence or quality assurance as an authorized commercial product.
A 2026 analysis identified 33 compounded semaglutide or tirzepatide products that differed from approved medicines [7]:
The key point is that “contains semaglutide” does not automatically mean “equivalent to an approved semaglutide medicine.”
The risks increase further with illegal online sellers. In a 2024 study, semaglutide purchased from unauthorized sources contained 29-39% more drugs than stated on the label, while measured purity was only 7.7-14.4% despite claims of 99% purity. Endotoxins (substances that can trigger harmful inflammatory reactions) were detected in every sample tested [8].
At that point, the question is no longer simply whether semaglutide causes nausea. It is whether you know what you are injecting.
Conclusion
There is no category of peptide that is universally safe or unsafe.
What matters is whether the specific molecule has been properly studied in humans, whether an established dose exists, whether the intended benefit is supported by evidence, whether the product comes through a regulated supply chain, and whether its use is medically supervised.
For GLP-1 therapies, we increasingly have strong answers to those questions. For many peptides marketed for recovery, muscle growth, regeneration, or longevity, the evidence is still developing.
That does not make these peptides uninteresting. On the contrary, their ability to influence highly specific biological pathways is what makes them such an exciting area of research. Some experimental peptides may ultimately become critical tools for treating disease or improving aspects of healthy aging.
Longevity research must remain open to emerging science. Lack of evidence of harm is not evidence of safety, but lack of evidence today does not mean lack of potential tomorrow. The goal is to separate hype from reality while giving promising ideas the rigorous testing they need to become meaningful advances.
Our educational articles are not here to tell readers what they should or should not do. Our role is to clarify where the science stands, so readers can better understand both the promise and the limitations of emerging longevity interventions and make informed decisions for themselves.
References
- Mendias CL, Awan TM. Safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance. Sports Medicine. 2026;56(8):1921–1935. doi:10.1007/s40279-026-02437-0.
- Mateescu DM, Gavrilescu DM, Constantinescu FE, et al. BPC-157 as an investigational peptide therapeutic: biopharmaceutical challenges, formulation strategies, and translational development barriers. Pharmaceutics. 2026;18(5):625. doi:10.3390/pharmaceutics18050625.
- Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology. 2026;17:1822475. doi:10.3389/fendo.2026.1822475.
- Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nature Reviews Drug Discovery. 2025;24(8):631–650. doi:10.1038/s41573-025-01183-8.
- Vidal J, Flores L, Jiménez A, Pané A, de Hollanda A. What is the evidence regarding the safety of new obesity pharmacotherapies. International Journal of Obesity. 2025;49(3):402–411. doi:10.1038/s41366-024-01488-5.
- Barazzoni R, Monami M, Buscemi S, et al. Efficacy and safety of European Medicines Agency-approved pharmacological, endoscopic, and surgical treatments in different classes of obesity. Diabetes, Obesity and Metabolism. 2026;28(1):358–378. doi:10.1111/dom.70204.
- Belcourt J, Sapowadia A, White CM. Compounded semaglutide and tirzepatide products use unique formulations but efficacy and safety largely unknown. Annals of Pharmacotherapy. 2026;60(9):902–906. doi:10.1177/10600280261421979.
- Ashraf AR, Mackey TK, Vida RG, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription. Journal of Medical Internet Research. 2024;26. doi:10.2196/65440.
- Lambson JE, Flegal SC, Johnson AR. Administration errors of compounded semaglutide reported to a poison control center—case series. Journal of the American Pharmacists Association. 2023;63(5):1643–1645. doi:10.1016/j.japh.2023.06.017.
- Achilleos K. Beyond efficacy: ensuring safety in peptide therapeutics through immunogenicity assessment. Journal of Peptide Science. 2025;31(6). doi:10.1002/psc.70016.